Mankind Pharma Q4 FY26 Earnings Call Transcript Released
Mankind Pharma's Q4 FY26 revenue grew 11.8% YoY to ₹3,443 crore, with full-year revenue at ₹14,278 crore, up 17.0%. Adjusted EBITDA margin for Q4 was 27.1%, and for the full year was 25.4%. Domestic revenue grew 13.4% in Q4. The company expects FY27 to be a better year with double-digit growth.
The announcement is a transcript of an earnings call, which provides detailed financial performance and future outlook. While positive, it's a post-results disclosure and doesn't contain new material events that would significantly alter the company's fundamental valuation in the short term.
The company reported strong revenue growth for Q4 FY26 and the full year FY26, along with improved EBITDA margins and positive outlook for FY27. The management expressed confidence in future growth.
Mankind Pharma Limited has released the transcript of its Investor Conference Call for Q4 and FY26, which was held on Wednesday, May 20, 2026, at 12:00 Noon (IST). The transcript is available on the company's website.
During the call, the management provided an update on the company's performance. For Q4 FY26, overall revenue increased by 11.8% year-on-year to ₹3,443 crores with an adjusted EBITDA margin of 27.1%. For the full year FY26, revenue grew by 17.0% year-on-year to ₹14,278 crores with an adjusted EBITDA margin of 25.4%. Domestic revenue, excluding Consumer Healthcare, increased by 12.9% in Q4 FY26, driven by double-digit growth in Mankind Domestic business and robust growth in the PSV specialty business. For the full year FY26, overall domestic revenue increased by 14.4% year-on-year. The company highlighted an improved volume growth of 2.3% in FY26 compared to 0.5% in the previous year. Mankind's overall PCPM also improved to ₹7.2 lakh per month in FY26 from ₹6.5 lakh in FY25.
The company also reported strong performance in chronic therapies, with the anti-diabetes segment growing by 14.7% and cardiac by 11.6% in Q4 FY26. Mankind's chronic share increased by 120 basis points year-on-year to approximately 40% in Q4 FY26 and by 190 basis points to approximately 39% for the full financial year 2026. The number of ₹200 crore brands increased to 13 from 11 in FY25, while ₹50 crore brands increased to 54 from 49 in FY25. The OTC business revenue increased by 20% to ₹213 crores in Q4 FY26, driven by strong growth in modern trade and e-commerce channels.
Management expressed confidence in regaining growth momentum and indicated that FY27 is expected to be a better year compared to FY26, with a focus on specialty chronic therapies and R&D-led innovation. The company aims for double-digit top-line growth in FY27 and expects EBITDA margins to be better than FY26, in the range of 25.5% to 26.5%. The company has also launched its GLP-1 pen approximately a month ago and is focusing on adjacent therapies like vitamins, minerals, and proteins.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.